Stocktoria
LENZ Therapeutics, Inc. LENZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-25
Chart by TradingView
2/9
Piotroski F — financial health
15.45
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $19.1M | $0 | — | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M |
| Operating cash flow | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
| Shareholders' equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M |
| Ratios | |||||
| Operating margin | -477.5% | — | — | — | — |
| Net margin | -430.3% | — | — | — | — |
| FCF margin | -366.7% | — | — | — | — |
| Return on assets | -26.8% | -23.1% | -99.4% | -31.4% | -17.6% |
| Return on equity | -28.9% | -24.4% | 75.5% | 418.1% | -18.4% |
| Current ratio | 14.23 | 20.36 | 3.63 | 21.11 | 31.44 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 15.45 (safe)
- Working capital / assets 0.916
- Retained earnings / assets -0.743
- EBIT / assets -0.298
- Equity / liabilities 13.202
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001815776 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.